New drug cocktail shows promise for Tough-to-Treat myeloma
NCT ID NCT03798678
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 40 times
Summary
This early-stage trial tests a new drug (CB-839 HCl) combined with two standard treatments for multiple myeloma that has returned or is not responding. The main goal is to find the safest dose and see how well the combination works. About 36 adults with relapsed or refractory multiple myeloma will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
Yale University
New Haven, Connecticut, 06520, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.